India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Amgen India investment totals $200 million through 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Cancer cases in India estimated to reach 1.57 million in 2025
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Subscribe To Our Newsletter & Stay Updated